Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): A randomised, multicentre, open-label, phase 2 study Journal Article


Authors: Bekaii-Saab, T. S.; Ou, F. S.; Ahn, D. H.; Boland, P. M.; Ciombor, K. K.; Heying, E. N.; Dockter, T. J.; Jacobs, N. L.; Pasche, B. C.; Cleary, J. M.; Meyers, J. P.; Desnoyers, R. J.; McCune, J. S.; Pedersen, K.; Barzi, A.; Chiorean, E. G.; Sloan, J.; Lacouture, M. E.; Lenz, H. J.; Grothey, A.
Article Title: Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): A randomised, multicentre, open-label, phase 2 study
Journal Title: Lancet Oncology
Volume: 20
Issue: 8
ISSN: 1470-2045
Publisher: Elsevier Science, Inc.  
Date Published: 2019-08-01
Start Page: 1070
End Page: 1082
Language: English
ACCESSION: 137777198
DOI: 10.1016/s1470-2045(19)30272-4
PROVIDER: EBSCOhost
PROVIDER: cin20
PUBMED: 31262657
DOI/URL:
Notes: Accession Number: 137777198 -- Entry Date: In Process -- Revision Date: 20190801 -- Publication Type: Article -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 100957246. -- Source: cin20
Altmetric Score
MSK Authors
  1. Mario E Lacouture
    280 Lacouture